This morning, Compass Pathways shared the first cut of Phase 3 data for a classical psychedelic, reporting a statistically significant MADRS difference vs. placebo and a reassuring safety profile in its trial of COMP360 psilocybin for treatment-resistant depression. Here, we provide our quick-take analysis and speak with company execs about the news.